Hakooz N - Search Results

1

Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans.

Carlile DJ, Hakooz N, Bayliss MK, Houston JB. Carlile DJ, et al. Among authors: hakooz n. Br J Clin Pharmacol. 1999 Jun;47(6):625-35. doi: 10.1046/j.1365-2125.1999.00935.x. Br J Clin Pharmacol. 1999. PMID: 10383540 Free PMC article.

2

Prediction of metabolic clearance using cryopreserved human hepatocytes: kinetic characteristics for five benzodiazepines.

Hallifax D, Rawden HC, Hakooz N, Houston JB. Hallifax D, et al. Among authors: hakooz n. Drug Metab Dispos. 2005 Dec;33(12):1852-8. doi: 10.1124/dmd.105.005389. Epub 2005 Sep 20. Drug Metab Dispos. 2005. PMID: 16174807

3

Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance.

Hakooz N, Ito K, Rawden H, Gill H, Lemmers L, Boobis AR, Edwards RJ, Carlile DJ, Lake BG, Houston JB. Hakooz N, et al. Pharm Res. 2006 Mar;23(3):533-9. doi: 10.1007/s11095-006-9531-2. Epub 2006 Feb 28. Pharm Res. 2006. PMID: 16505976

4

Kinetics of drug metabolism in rat liver slices: IV. Comparison of ethoxycoumarin clearance by liver slices, isolated hepatocytes, and hepatic microsomes from rats pretreated with known modifiers of cytochrome P-450 activity.

Carlile DJ, Hakooz N, Houston JB. Carlile DJ, et al. Among authors: hakooz n. Drug Metab Dispos. 1999 Apr;27(4):526-32. Drug Metab Dispos. 1999. PMID: 10101148

5

Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population.

Yousef AM, Bulatova NR, Newman W, Hakooz N, Ismail S, Qusa H, Zahran F, Anwar Ababneh N, Hasan F, Zaloom I, Khayat G, Al-Zmili R, Naffa R, Al-Diab O. Yousef AM, et al. Among authors: hakooz n. Mol Biol Rep. 2012 Oct;39(10):9423-33. doi: 10.1007/s11033-012-1807-5. Epub 2012 Jun 22. Mol Biol Rep. 2012. PMID: 22722998

6

Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities.

Hakooz NM. Hakooz NM. Curr Drug Metab. 2009 May;10(4):329-38. doi: 10.2174/138920009788499003. Curr Drug Metab. 2009. PMID: 19519341 Review.

7

Polymorphisms in Factor II and Factor V thrombophilia genes among Circassians in Jordan.

Dajani R, Arafat A, Hakooz N, Al-Abbadi Z, Yousef AM, El Khateeb M, Quadan F. Dajani R, et al. Among authors: hakooz n. J Thromb Thrombolysis. 2013 Jan;35(1):83-9. doi: 10.1007/s11239-012-0772-0. J Thromb Thrombolysis. 2013. PMID: 23011539 Clinical Trial.

8

Effects of dietary broccoli on human in vivo caffeine metabolism: a pilot study on a group of Jordanian volunteers.

Hakooz N, Hamdan I. Hakooz N, et al. Curr Drug Metab. 2007 Jan;8(1):9-15. doi: 10.2174/138920007779315080. Curr Drug Metab. 2007. PMID: 17266520 Clinical Trial.

9

Interethnic Variations of UGT1A1 and UGT1A7 Polymorphisms in the Jordanian Population.

Abudahab S, Hakooz N, Jarrar Y, Al Shahhab M, Saleh A, Zihlif M, Dajani R. Abudahab S, et al. Among authors: hakooz n. Curr Drug Metab. 2019;20(5):399-410. doi: 10.2174/1389200220666190528085151. Curr Drug Metab. 2019. PMID: 31132973

10

Prevalence of desloratadine poor metabolizer phenotype in healthy Jordanian males.

Hakooz N, Salem II. Hakooz N, et al. Biopharm Drug Dispos. 2012 Jan;33(1):15-21. doi: 10.1002/bdd.1770. Epub 2012 Feb 5. Biopharm Drug Dispos. 2012. PMID: 22271705 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results